Previous close | 12.69 |
Open | 12.39 |
Bid | 12.55 x 300 |
Ask | 12.63 x 100 |
Day's range | 12.37 - 12.64 |
52-week range | 5.85 - 17.44 |
Volume | |
Avg. volume | 135,139 |
Market cap | 624.578M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
On June 14, 2024, Jon Congleton, CEO of Mineralys Therapeutics Inc (NASDAQ:MLYS), executed a sale of 72,797 shares of the company, according to the SEC Filing.
On June 11, 2024, Adam Levy, the Chief Financial Officer and Secretary of Mineralys Therapeutics Inc (NASDAQ:MLYS), sold 96,815 shares of the company.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript May 11, 2024 Mineralys Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the Mineralys First Quarter 2024 Earnings Conference Call. At […]